Singapore markets closed

Cellectis S.A. (CLLS)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
1.8900-0.0600 (-3.08%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.9500
Open1.8500
Bid1.8200 x 100
Ask1.9400 x 100
Day's range1.8200 - 1.9300
52-week range0.9630 - 3.7740
Volume205,099
Avg. volume52,738
Market cap189.178M
Beta (5Y monthly)3.09
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing

    NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a manuscript in Scientific Reports, demonstrating how three key factors can be determinant for efficient TALE base editing. TALE base editors are a recent and important addition to the gene editing landscape. By design, TALE

  • GlobeNewswire

    Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications

    NEW YORK, June 12, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a scientific article in Nature Communications, unveiling a non-viral gene therapy approach for sickle cell disease. Sickle cell disease (SCD) is one of the most common inherited diseases worldwide. SCD is caused by a single

  • GlobeNewswire

    Monthly information on share capital and company voting rights

    (Article 223-16 of General Regulation of the French financial markets authority) PARIS, June 05, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting rights05/31/2024100,093,63588,029,374 For further information on Cellectis, please contact: Media contact: Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@cellectis.com Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 4